LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation.

    Viklicky, Ondrej / Slatinska, Janka / Janousek, Libor / Rousse, Juliette / Royer, Pierre-Joseph / Toutain, Pierre-Louis / Cozzi, Emanuele / Galli, Cesare / Evanno, Gwenaelle / Duvaux, Odile / Bach, Jean-Marie / Soulillou, Jean-Paul / Giral, Magali / Vanhove, Bernard / Blancho, Gilles

    Transplantation

    2024  

    Abstract: Background: Polyclonal rabbit antithymocyte globulins (ATGs) are commonly used in organ transplantation as induction. Anti-N-glycolylneuraminic acid carbohydrate antibodies which develop in response to rabbit carbohydrate antigens might lead to unwanted ...

    Abstract Background: Polyclonal rabbit antithymocyte globulins (ATGs) are commonly used in organ transplantation as induction. Anti-N-glycolylneuraminic acid carbohydrate antibodies which develop in response to rabbit carbohydrate antigens might lead to unwanted systemic inflammation. LIS1, the first new generation of antilymphocyte globulins (ALGs) derived from double knockout swine, lacking carbohydrate xenoantigens was already tested in nonhuman primates and rodent models.
    Methods: This open-label, single-site, dose escalation, first-in-human, phase 1 study evaluated the safety, T cell depletion, pharmacokinetics, and pharmacodynamics of LIS1. In an ascending dose cohort (n = 5), a primary kidney transplant recipient at low immunologic risk (panel reactive antibody [PRA] < 20%), received LIS1 for 5 d at either 0.6, 1, 3, 6, or 8 mg/kg. After each patient completed treatment, the data safety monitoring board approved respective dose escalation. In the therapeutic dose cohort (n = 5) in patients with PRA <50% without donor specific antibodies, 2 patients received 8 mg/kg and 3 patients 10 mg/kg.
    Results: CD3+ T cell depletion <100/mm3 at day 2 was observed in all patients who received 6, 8, and 10 mg/kg of LIS1. The terminal half-life of LIS1 was 33.7 d with linearity in its disposition. Lymphocyte repopulation was fast and pretransplant lymphocyte subpopulation counts recovered within 2-4 wk. LIS1 was well tolerated, neither cytokine release syndrome nor severe thrombocytopenia or leukopenia were noticed. Antibodies to LIS1 were not detected.
    Conclusions: In this first-in-human trial, genome-edited swine-derived polyclonal LIS1 ALG was well tolerated, did not elicit antidrug antibodies, and caused time-limited T cell depletion in low- and medium-risk kidney transplant recipients.
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.

    Ciron, Carine / Morice, Pierre / Rousse, Juliette / Roy, Patrice / Royer, Pierre-Joseph / Gauthier, Olivier / Brouard, Sophie / Duvaux, Odile / Bassissi, Firas / Vanhove, Bernard

    JCI insight

    2024  Volume 9, Issue 3

    Abstract: Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces ... ...

    Abstract Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces susceptibility to tumor escape. Owing to the recent availability of glyco-humanized pAb (GH-pAb) with acceptable clinical toxicology profile, we revisited use of pAb in oncology and highlighted their therapeutic potential against multiple cancer types. Murine antitumor pAb were generated after repeated immunization of rabbits with murine tumor cell lines from hepatocarcinoma, melanoma, and colorectal cancers. Antitumor pAb recognized and showed cytotoxicity against their targets without cross-reactivity with healthy tissues. In vivo, pAb are effective alone; moreover, these pAb synergize with immune checkpoint inhibitors like anti-PD-L1 in several cancer models. They elicited an antitumor host immune response and prevented metastases. The anticancer activity of pAb was also confirmed in xenografted NMRI nude mice using GH-pAb produced by repeated immunization of pigs with human tumor cell lines. In conclusion, the availability of bioengineered GH-pAb allows for revisiting of passive immunotherapy with oncolytic pAb to fight against solid tumor and cancer metastasis.
    MeSH term(s) Humans ; Rabbits ; Animals ; Mice ; Swine ; Immune Checkpoint Inhibitors ; Mice, Nude ; Immunization ; Melanoma/therapy ; Cell Line, Tumor ; Antibodies, Neoplasm/pharmacology
    Chemical Substances Immune Checkpoint Inhibitors ; Antibodies, Neoplasm
    Language English
    Publishing date 2024-02-08
    Publishing country United States
    Document type Journal Article
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.166231
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation.

    Rousse, Juliette / Royer, Pierre-Joseph / Evanno, Gwénaëlle / Lheriteau, Elsa / Ciron, Carine / Salama, Apolline / Shneiker, Françoise / Duchi, Roberto / Perota, Andrea / Galli, Cesare / Cozzi, Emmanuele / Blancho, Gilles / Duvaux, Odile / Brouard, Sophie / Soulillou, Jean-Paul / Bach, Jean-Marie / Vanhove, Bernard

    Frontiers in immunology

    2023  Volume 14, Page(s) 1137629

    Abstract: Anti-thymocyte or anti-lymphocyte globulins (ATGs/ALGs) are immunosuppressive drugs used in induction therapies to prevent acute rejection in solid organ transplantation. Because animal-derived, ATGs/ALGs contain highly immunogenic carbohydrate ... ...

    Abstract Anti-thymocyte or anti-lymphocyte globulins (ATGs/ALGs) are immunosuppressive drugs used in induction therapies to prevent acute rejection in solid organ transplantation. Because animal-derived, ATGs/ALGs contain highly immunogenic carbohydrate xenoantigens eliciting antibodies that are associated with subclinical inflammatory events, possibly impacting long-term graft survival. Their strong and long-lasting lymphodepleting activity also increases the risk for infections. We investigated here the
    MeSH term(s) Rabbits ; Animals ; Swine ; Organ Transplantation ; Lymphocytes ; Transplantation, Homologous ; Globulins ; B-Lymphocytes
    Chemical Substances Globulins
    Language English
    Publishing date 2023-02-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1137629
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)

    Vanhove, Bernard / Marot, Stephane Sylvain / Evanno, Gwenaelle / Mallet, Isabelle / Rouvray, Gaetane / Shneiker, Francoise / Mevel, Edwige / Ciron, Carine / Rousse, Juliette / Royer, Pierre-Joseph / Lheriteau, Elsa / Raffi, Francois / Duvaux, Odile / Marcelin, Anne-Genevieve / Calvez, Vincent

    bioRxiv

    Abstract: B.1.1.529 is the SARS-CoV-2 variant designated Omicron by the WHO in November 2021. It is a highly divergent variant with a high number of mutations, including 26-32 mutations in the spike protein among which 15 in the Receptor Binding Domain (RBD) ... ...

    Abstract B.1.1.529 is the SARS-CoV-2 variant designated Omicron by the WHO in November 2021. It is a highly divergent variant with a high number of mutations, including 26-32 mutations in the spike protein among which 15 in the Receptor Binding Domain (RBD) including at the human angiotensin converting enzyme 2 (ACE-2) receptor interacting interface. Because of a decreased affinity for the ACE-2 receptor and a geometric reorganization of the S1-S2 cleavage site, the Omicron variant is predicted to not have a significant infectivity advantage over the delta variant and to be less pathogenic than Delta. However, in Omicron, neutralizing epitopes are greatly affected, suggesting that current vaccines and neutralizing monoclonal antibodies might confer reduced protection against this variant. In contrast, we and others previously demonstrated that polyclonal antibodies against SARS-CoV-2 RBD obtained from hyperimmunized animal hosts do maintain their neutralizing properties against Alpha to Delta. Here, we confirmed these findings by showing that XAV-19, a swine glyco-humanized polyclonal antibody retains full neutralizing activity against Omicron.
    Keywords covid19
    Language English
    Publishing date 2022-01-26
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2022.01.26.477856
    Database COVID19

    Kategorien

  5. Article ; Online: Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients.

    Rousse, Juliette / Salama, Apolline / Leviatan Ben-Arye, Shani / Hruba, Petra / Slatinska, Janka / Evanno, Gwénaëlle / Duvaux, Odile / Blanchard, Dominique / Yu, Hai / Chen, Xi / Bach, Jean-Marie / Padler-Karavani, Vered / Viklicky, Ondrej / Soulillou, Jean-Paul

    European journal of clinical investigation

    2019  Volume 49, Issue 4, Page(s) e13069

    Abstract: Antibodies of non-human mammals are glycosylated with carbohydrate antigens, such as galactose-α-1-3-galactose (α-Gal) and N-glycolylneuraminic acid (Neu5Gc). These non-human carbohydrate antigens are highly immunogenic in humans due to loss-of-function ... ...

    Abstract Antibodies of non-human mammals are glycosylated with carbohydrate antigens, such as galactose-α-1-3-galactose (α-Gal) and N-glycolylneuraminic acid (Neu5Gc). These non-human carbohydrate antigens are highly immunogenic in humans due to loss-of-function mutations of the key genes involved in their synthesis. Such immunogenic carbohydrates are expressed on therapeutic polyclonal rabbit anti-human T-cell IgGs (anti-thymocyte globulin; ATG), the most popular induction treatment in allograft recipients. To decipher the quantitative and qualitative response against these antigens in immunosuppressed patients, particularly against Neu5Gc, which may induce endothelial inflammation in both the graft and the host. We report a prospective study of the antibody response against α-Gal and Neu5Gc-containing glycans following rabbit ATG induction compared to controls. We show a drop in the overall levels of anti-Neu5Gc antibodies at 6 and 12 months post-graft compared to the pre-existing levels due to the major early immunosuppression. However, in contrast, in a cross-sectional study there was a highly significant increase in anti-Neu5Gc IgGs levels at 6 months post-graft in the ATG-treated compared to non-treated patients(P = 0.007), with a clear hierarchy favouring anti-Neu5Gc over anti-Gal response. A sialoglycan microarray analysis revealed that the increased anti-Neu5Gc IgG response was still highly diverse against multiple different Neu5Gc-containing glycans. Furthermore, some of the ATG-treated patients developed a shift in their anti-Neu5Gc IgG repertoire compared with the baseline, recognizing different patterns of Neu5Gc-glycans. In contrast to Gal, Neu5Gc epitopes remain antigenic in severely immunosuppressed patients, who also develop an anti-Neu5Gc repertoire shift. The clinical implications of these observations are discussed.
    MeSH term(s) Adult ; Aged ; Antibodies/immunology ; Antibodies/metabolism ; Case-Control Studies ; Cross-Sectional Studies ; Female ; Humans ; Immunity, Cellular/physiology ; Immunoglobulin G/pharmacology ; Immunologic Factors/pharmacology ; Kidney Transplantation/methods ; Male ; Middle Aged ; Neuraminic Acids/immunology ; Prospective Studies ; Thymocytes/immunology ; Transplantation Immunology/physiology ; Transplantation, Homologous
    Chemical Substances Antibodies ; Immunoglobulin G ; Immunologic Factors ; Neuraminic Acids ; N-glycolylneuraminic acid (1113-83-3)
    Language English
    Publishing date 2019-02-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 186196-7
    ISSN 1365-2362 ; 0014-2972 ; 0960-135X
    ISSN (online) 1365-2362
    ISSN 0014-2972 ; 0960-135X
    DOI 10.1111/eci.13069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.

    Salama, Apolline / Evanno, Gwénaëlle / Lim, Noha / Rousse, Juliette / Le Berre, Ludmilla / Nicot, Arnaud / Bach, Jean-Marie / Brouard, Sophie / Harris, Kristina M / Ehlers, Mario R / Gitelman, Stephen E / Soulillou, Jean-Paul

    Transplantation

    2017  Volume 101, Issue 10, Page(s) 2501–2507

    Abstract: Background: Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppressive drugs used to prevent or treat organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases. However, ... ...

    Abstract Background: Polyclonal antihuman thymocyte rabbit IgGs (antithymocyte globulin [ATG]) are popular immunosuppressive drugs used to prevent or treat organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases. However, animal-derived glycoproteins are also strongly immunogenic and rabbit ATG induces serum sickness disease in almost all patients without additional immunosuppressive drugs, as seen in the Study of Thymoglobulin to arrest Type 1 Diabetes (START) trial of ATG therapy in new-onset type 1 diabetes.
    Methods: Using enzyme-linked immunosorbent assay, we analyzed serial sera from the START study to decipher the various anti-ATG specificities developed by the patients in this study: antitotal ATG, but also antigalactose-α1-3-galactose (Gal) and anti-Neu5Gc antibodies, 2 xenocarbohydrate epitopes present on rabbit IgG glycans and lacking in humans.
    Results: We show that diabetic patients have substantial levels of preexisting antibodies of the 3 specificities, before infusion, but of similar levels as healthy individuals. ATG treatment resulted in highly significant increases of both IgM (for anti-ATG and anti-Neu5Gc) and IgG (for anti-ATG, -Gal, and -Neu5Gc), peaking at 1 month and still detectable 1 year postinfusion.
    Conclusions: Treatment with rabbit polyclonal IgGs in the absence of additional immunosuppression results in a vigorous response against Gal and Neu5Gc epitopes, contributing to an inflammatory environment that may compromise the efficacy of ATG therapy. The results also suggest using IgGs lacking these major xenoantigens may improve safety and efficacy of ATG treatment.
    MeSH term(s) Adolescent ; Adult ; Animals ; Antilymphocyte Serum/therapeutic use ; Child ; Diabetes Mellitus, Type 1/surgery ; Enzyme-Linked Immunosorbent Assay ; Female ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Humans ; Immunosuppression/methods ; Immunosuppressive Agents/therapeutic use ; Male ; Pancreas Transplantation/adverse effects ; Rabbits ; Young Adult
    Chemical Substances Antilymphocyte Serum ; Immunosuppressive Agents ; thymoglobulin (D7RD81HE4W)
    Language English
    Publishing date 2017-10
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000001686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

    Vanhove, Bernard / Duvaux, Odile / Rousse, Juliette / Royer, Pierre-Joseph / Evanno, Gwénaëlle / Ciron, Carine / Lheriteau, Elsa / Vacher, Laurent / Gervois, Nadine / Oger, Romain / Jacques, Yannick / Conchon, Sophie / Salama, Apolline / Duchi, Roberto / Lagutina, Irina / Perota, Andrea / Delahaut, Philippe / Ledure, Matthieu / Paulus, Melody /
    So, Ray T / Mok, Chris Ka-Pun / Bruzzone, Roberto / Bouillet, Marc / Brouard, Sophie / Cozzi, Emanuele / Galli, Cesare / Blanchard, Dominique / Bach, Jean-Marie / Soulillou, Jean-Paul

    European journal of immunology

    2021  Volume 51, Issue 6, Page(s) 1412–1422

    Abstract: Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes. However, heterologous antibodies trigger human ... ...

    Abstract Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes. However, heterologous antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrates, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the α1,3-galactose, potentially leading to serum sickness or allergy. Here, we immunized cytidine monophosphate-N-acetylneuraminic acid hydroxylase and α1,3-galactosyl-transferase (GGTA1) double KO pigs with the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor binding domain to produce glyco-humanized polyclonal neutralizing antibodies lacking Neu5Gc and α1,3-galactose epitopes. Animals rapidly developed a hyperimmune response with anti-SARS-CoV-2 end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10 000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized spike/angiotensin converting enzyme-2 interaction at a concentration <1 μg/mL, and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. We also found that pig GH-pAb Fc domains fail to interact with human Fc receptors, thereby avoiding macrophage-dependent exacerbated inflammatory responses and a possible antibody-dependent enhancement. These data and the accumulating safety advantages of using GH-pAbs in humans warrant clinical assessment of XAV-19 against COVID-19.
    MeSH term(s) Animals ; Animals, Genetically Modified/genetics ; Animals, Genetically Modified/immunology ; Antibodies, Neutralizing/genetics ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/pharmacology ; Antibodies, Viral/genetics ; Antibodies, Viral/immunology ; Antibodies, Viral/pharmacology ; COVID-19/genetics ; COVID-19/immunology ; COVID-19/therapy ; Galactosyltransferases/deficiency ; Galactosyltransferases/immunology ; HEK293 Cells ; Humans ; Immunization, Passive ; SARS-CoV-2/genetics ; SARS-CoV-2/immunology ; Sialic Acids/genetics ; Sialic Acids/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Swine
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; N-(O-acetyl)glycoloylneuraminic acid ; Sialic Acids ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Galactosyltransferases (EC 2.4.1.-) ; alpha-1,3-galactosyltransferase 1, porcine (EC 2.4.1.-)
    Language English
    Publishing date 2021-03-02
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202049072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.

    Vanhove, Bernard / Duvaux, Odile / Rousse, Juliette / Royer, Pierre-Joseph / Evanno, Gwénaëlle / Ciron, Carine / Lheriteau, Elsa / Vacher, Laurent / Gervois, Nadine / Oger, Romain / Jacques, Yannick / Conchon, Sophie / Salama, Apolline / Duchi, Roberto / Lagutina, Irina / Perota, Andrea / Delahaut, Philippe / Ledure, Matthieu / Paulus, Melody /
    So, Ray T / Mok, Chris Ka-Pun / Bruzzone, Roberto / Bouillet, Marc / Brouard, Sophie / Cozzi, Emanuele / Galli, Cesare / Blanchard, Dominique / Bach, Jean-Marie / Soulillou, Jean-Paul

    bioRxiv : the preprint server for biology

    2020  

    Abstract: Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Many monoclonal antibodies (mAbs) have been developed but appear ... ...

    Abstract Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Many monoclonal antibodies (mAbs) have been developed but appear insufficient to neutralize SARS-CoV-2 unless two or three of them are being combined. Therefore, heterologous polyclonal antibodies of animal origin, that have been used for decades to fight against infectious agents might represent a highly efficient alternative to the use of CP or mAbs in COVID-19 by targeting multiple antigen epitopes. However, conventional heterologous polyclonal antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrate epitopes, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal α1,3-galactose (αGal), ultimately forming immune complexes and potentially leading to serum sickness or allergy. To circumvent these drawbacks, we engineered animals lacking the genes coding for the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and α1,3-galactosyl-transferase (GGTA1) enzymes to produce glyco-humanized polyclonal antibodies (GH-pAb) lacking Neu5Gc and α-Gal epitopes. We found that pig IgG Fc domains fail to interact with human Fc receptors and thereby should confer the safety advantage to avoiding macrophage dependent exacerbated inflammatory responses, a drawback possibly associated with antibody responses against SARS-CoV-2 or to avoiding a possible antibody-dependent enhancement (ADE). Therefore, we immunized CMAH/GGTA1 double knockout (DKO) pigs with the SARS-CoV-2 spike receptor-binding domain (RBD) to elicit neutralizing antibodies. Animals rapidly developed a hyperimmune response with anti-SARS-CoV-2 end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10,000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized Spike/angiotensin converting enzyme-2 (ACE-2) interaction at a concentration < 1μg/mL and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. These data and the accumulating safety advantages of using glyco-humanized swine antibodies in humans warranted clinical assessment of XAV-19 to fight against COVID-19.
    Language English
    Publishing date 2020-10-28
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.07.25.217158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

    Vanhove, Bernard / Duvaux, Odile / Rousse, Juliette / Royer, Pierre-Joseph / Evanno, Gwenaelle / Ciron, Carine / Lheriteau, Elsa / Vacher, Laurent / Gervois, Nadine / Oger, Romain / Jacques, Yannick / Salama, Apolline / Duchi, Roberto / Perota, Andrea / Delahaut, Philippe / Ledure, Matthieu / Paulus, Melody / So, Ray / Mok, Chris Ka Pun /
    Bruzzone, Roberto / Bouillet, Marc / Brouard, Sophie / Cozzi, Emanuele / Galli, Cesare / Blanchard, Dominique / Bach, Jean-Marie / Soulillou, Jean-Paul

    bioRxiv

    Abstract: Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Heterologous polyclonal antibodies of animal origin have been ... ...

    Abstract Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Heterologous polyclonal antibodies of animal origin have been used to fight against infectious agents and are a possible alternative to the use of CP in SARS-CoV-2 disease. However, heterologous polyclonal antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrate epitopes, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal alpha1,3-galactose (a-Gal), ultimately forming immune complexes and potentially leading to serum sickness or allergy. To circumvent these drawbacks, we engineered animals lacking the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and alpha1,3-galactosyltransferase (GGTA1) enzymes to produce glyco-humanized polyclonal antibodies (GH-pAb) lacking Neu5Gc and a-Gal epitopes. We also found that these IgG Fc domains fail to interact with human Fc receptors and thereby should confer the safety advantage to avoiding macrophage dependent exacerbated inflammatory responses or elicit antibody-dependent enhancement (ADE), two drawbacks possibly associated with antibody responses against SARS-CoV-2. Therefore, we immunized CMAH/GGTA1 double knockout (DKO) pigs with the SARS-CoV-2 spike receptor binding domain (RBD) domain to elicit neutralizing antibodies. Animals rapidly developed hyperimmune sera with end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10,000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized Spike/ACE-2 interaction at a concentration < 1microgram/mL and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. These data and the accumulating safety advantages of using glyco-humanized swine antibodies in humans warrant clinical assessment of XAV-19 to fight against COVID-19.
    Keywords covid19
    Language English
    Publishing date 2020-07-25
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2020.07.25.217158
    Database COVID19

    Kategorien

  10. Article ; Online: High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

    Vanhove, Bernard / Duvaux, Odile / Rousse, Juliette / Royer, Pierre-Joseph / Evanno, Gwénaëlle / Ciron, Carine / Lheriteau, Elsa / Vacher, Laurent / Gervois, Nadine / Oger, Romain / Jacques, Yannick / Conchon, Sophie / Salama, Apolline / Duchi, Roberto / Lagutina, Irina / Perota, Andrea / Delahaut, Philippe / Ledure, Matthieu / Paulus, Melody /
    So, Ray T. / Mok, Chris Ka-Pun / Bruzzone, Roberto / Bouillet, Marc / Brouard, Sophie / Cozzi, Emanuele / Galli, Cesare / Blanchard, Dominique / Bach, Jean-Marie / Soulillou, Jean-Paul

    bioRxiv

    Abstract: Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Many monoclonal antibodies (mAbs) have been developed but appear ... ...

    Abstract Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Many monoclonal antibodies (mAbs) have been developed but appear insufficient to neutralize SARS-CoV-2 unless two or three of them are being combined. Therefore, heterologous polyclonal antibodies of animal origin, that have been used for decades to fight against infectious agents might represent a highly efficient alternative to the use of CP or mAbs in COVID-19 by targeting multiple antigen epitopes. However, conventional heterologous polyclonal antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrate epitopes, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal α1,3-galactose (αGal), ultimately forming immune complexes and potentially leading to serum sickness or allergy. To circumvent these drawbacks, we engineered animals lacking the genes coding for the cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and α1,3-galactosyl-transferase (GGTA1) enzymes to produce glyco-humanized polyclonal antibodies (GH-pAb) lacking Neu5Gc and α-Gal epitopes. We found that pig IgG Fc domains fail to interact with human Fc receptors and thereby should confer the safety advantage to avoiding macrophage dependent exacerbated inflammatory responses, a drawback possibly associated with antibody responses against SARS-CoV-2 or to avoiding a possible antibody-dependent enhancement (ADE). Therefore, we immunized CMAH/GGTA1 double knockout (DKO) pigs with the SARS-CoV-2 spike receptor-binding domain (RBD) to elicit neutralizing antibodies. Animals rapidly developed a hyperimmune response with anti-SARS-CoV-2 end-titers binding dilutions over one to a million and end-titers neutralizing dilutions of 1:10,000. The IgG fraction purified and formulated following clinical Good Manufacturing Practices, named XAV-19, neutralized Spike/angiotensin converting enzyme-2 (ACE-2) interaction at a concentration < 1μg/mL and inhibited infection of human cells by SARS-CoV-2 in cytopathic assays. These data and the accumulating safety advantages of using glyco-humanized swine antibodies in humans warranted clinical assessment of XAV-19 to fight against COVID-19.
    Keywords covid19
    Publisher BioRxiv; WHO
    Document type Article ; Online
    DOI 10.1101/2020.07.25.217158
    Database COVID19

    Kategorien

To top